Investments → Case Study

ADC Therapeutics

ADC Therapeutics is a commercial-stage oncology-focused biotechnology company developing ADCs for patients with hematological malignancies & solid tumors. Exited via IPO in 2020.

Our portfolio

We invest wherever opportunity lives

Our portfolio proudly extends beyond verticals and asset classes

View all →

Contact

Let's reimagine capital together

It all begins with a conversation.

Get in touch